CN116947948A - Synthesis method of crotonoside and analogues thereof - Google Patents
Synthesis method of crotonoside and analogues thereof Download PDFInfo
- Publication number
- CN116947948A CN116947948A CN202310935349.3A CN202310935349A CN116947948A CN 116947948 A CN116947948 A CN 116947948A CN 202310935349 A CN202310935349 A CN 202310935349A CN 116947948 A CN116947948 A CN 116947948A
- Authority
- CN
- China
- Prior art keywords
- crotonin
- analogues
- reaction
- crotonoside
- synthesis method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001308 synthesis method Methods 0.000 title claims abstract description 8
- MIKUYHXYGGJMLM-UUOKFMHZSA-N Crotonoside Chemical compound C1=NC2=C(N)NC(=O)N=C2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O MIKUYHXYGGJMLM-UUOKFMHZSA-N 0.000 title abstract description 9
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 title abstract description 9
- 238000006243 chemical reaction Methods 0.000 claims abstract description 26
- 238000000034 method Methods 0.000 claims abstract description 12
- RRUDCFGSUDOHDG-UHFFFAOYSA-N acetohydroxamic acid Chemical compound CC(O)=NO RRUDCFGSUDOHDG-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960001171 acetohydroxamic acid Drugs 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- FRQCYMRNNSMXHG-UHFFFAOYSA-N 2-nitro-7h-purine Chemical class [O-][N+](=O)C1=NC=C2NC=NC2=N1 FRQCYMRNNSMXHG-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 4
- 150000001340 alkali metals Chemical class 0.000 claims abstract description 4
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims abstract description 4
- SRNFODIJXVPXHO-FSJWMSIRSA-N (4r,4ar,5'r,7r,8r,8as)-5'-(furan-3-yl)-4,7-dimethylspiro[1,3,4,4a,5,6,7,8a-octahydronaphthalene-8,3'-oxolane]-2,2'-dione Chemical compound C=1([C@H]2C[C@@]3(C(O2)=O)[C@H](C)CC[C@H]2[C@@H]3CC(=O)C[C@H]2C)C=COC=1 SRNFODIJXVPXHO-FSJWMSIRSA-N 0.000 claims description 20
- SRNFODIJXVPXHO-UHFFFAOYSA-N Crotonin Natural products CC1CC(=O)CC2C1CCC(C)C2(C(O1)=O)CC1C=1C=COC=1 SRNFODIJXVPXHO-UHFFFAOYSA-N 0.000 claims description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 4
- 230000002194 synthesizing effect Effects 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 125000006282 2-chlorobenzyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 150000001342 alkaline earth metals Chemical group 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims description 2
- -1 alkaline earth metal carbonate Chemical class 0.000 abstract description 4
- 239000000758 substrate Substances 0.000 abstract description 3
- 150000001875 compounds Chemical class 0.000 abstract 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
- 244000168525 Croton tiglium Species 0.000 description 3
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000002212 purine nucleoside Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- LLNAMUJRIZIXHF-CLFYSBASSA-N (z)-2-methyl-3-phenylprop-2-en-1-ol Chemical compound OCC(/C)=C\C1=CC=CC=C1 LLNAMUJRIZIXHF-CLFYSBASSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- DVNYTAVYBRSTGK-UHFFFAOYSA-N Aminoimidazole carboxamide Natural products NC(=O)C=1N=CNC=1N DVNYTAVYBRSTGK-UHFFFAOYSA-N 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- VCEVGFVRWPGRTD-UHFFFAOYSA-N C(=O)=C1N=CC2=NC=NC2=N1 Chemical class C(=O)=C1N=CC2=NC=NC2=N1 VCEVGFVRWPGRTD-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000221017 Euphorbiaceae Species 0.000 description 1
- 102100021455 Histone deacetylase 3 Human genes 0.000 description 1
- 101000899282 Homo sapiens Histone deacetylase 3 Proteins 0.000 description 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 238000007098 aminolysis reaction Methods 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 150000003834 purine nucleoside derivatives Chemical class 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/28—Oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
技术领域Technical field
本发明属于药物化学技术领域,具体涉及一种巴豆苷及其类似物的合成方法。The invention belongs to the technical field of medicinal chemistry, and specifically relates to a synthesis method of crotonin and its analogues.
背景技术Background technique
巴豆苷(Crotonoside,又叫异鸟苷,CAS1818-71-9),是一种天然核苷类化合物,最早从中药巴豆种子中分离得到。巴豆种子属于大戟科植物巴豆Crotontig liumL.的干燥成熟果实,是传统的中药材。巴豆苷是巴豆重要的活性成分。研究显示,巴豆苷具有多种生理活性,如能够增进肠道蠕动、降低血压,能够刺激大脑使AMP(腺苷酸)富集,对小鼠S180腹水瘤和Ehrlich实体肿瘤都有显著的抑制作用,可通过抑制FLT3和HDAC3/6在急性髓性白血病(AML)细胞中表现出选择性的后抑制作用,可以通过调节兔心室肌细胞钠钙通道而具有抗心律失常作用。另外,巴豆苷是生物体内RNA的结构片段鸟苷的异构体,可作为鸟苷类似物嵌入RNA片段中并进行基因表达,从而在生化研究中具有重要用途。其和巴豆苷类似的2-羰基嘌呤衍生物,也具有较好的生理活性。Crotonoside (also called isoguanosine, CAS1818-71-9) is a natural nucleoside compound, which was first isolated from the seeds of the traditional Chinese medicine Crotonoside. Croton seeds belong to the dried and mature fruits of Crotontig lium L., a plant of the Euphorbiaceae family, and are traditional Chinese medicinal materials. Crotonin is an important active component of Croton. Studies have shown that crotonin has a variety of physiological activities, such as increasing intestinal peristalsis, lowering blood pressure, stimulating the brain to enrich AMP (adenylate), and having a significant inhibitory effect on S180 ascites tumors and Ehrlich solid tumors in mice. , can show selective post-inhibitory effects in acute myeloid leukemia (AML) cells by inhibiting FLT3 and HDAC3/6, and can have anti-arrhythmic effects by regulating sodium and calcium channels in rabbit ventricular myocytes. In addition, crotonin is an isomer of guanosine, a structural fragment of RNA in organisms. It can be embedded into RNA fragments as a guanosine analog and perform gene expression, thus having important uses in biochemical research. Its 2-carbonylpurine derivative, which is similar to crotonin, also has good physiological activity.
目前,巴豆苷除了从天然资源中分离得到以外,化学合成法主要有以下三种路线:At present, in addition to isolating crotonin from natural resources, there are mainly three chemical synthesis routes:
1)2-取代(I、Cl或NH2)腺苷经过光照水解或重氮化反应得到,但是选择性差,收率很低,或者2-羟基-6-硫取代嘌呤核苷经氨解得到,但是原料合成难度大;1) 2-substituted (I, Cl or NH 2 ) adenosine can be obtained by light hydrolysis or diazotization reaction, but the selectivity is poor and the yield is very low, or 2-hydroxy-6-thio-substituted purine nucleoside can be obtained by aminolysis , but it is difficult to synthesize raw materials;
2)异鸟嘌呤经硅醚保护后和基团保护的核糖在TMSOTf或SnCl4催化下缩合,再脱除保护基得到,缺点是步骤多,收率低,异鸟嘌呤的合成难度也很大;2) After silicon ether protection, isoguanine is condensed with group-protected ribose under the catalysis of TMSOTf or SnCl 4 , and then the protecting group is removed. The disadvantage is that there are many steps, low yield, and the synthesis of isoguanine is also very difficult. ;
3)氨基咪唑甲酰胺核苷经环合仿生合成异鸟苷,但收率很低,不具有合成上的价值。3) Aminoimidazole carboxamide nucleoside is biomimically synthesized through cyclization of isoguanosine, but the yield is very low and has no synthetic value.
以上三种反应路线限制了巴豆苷合成规模的扩大。从廉价易得的原料合成得到巴豆苷可以避免从天然产物中分离、提取的繁琐步骤,也可以解决现有化学合成方法中存在的收率低等问题,对于扩大巴豆苷的来源,从而扩大其应用范围具有重要意义。The above three reaction routes limit the expansion of the synthesis scale of crotonin. Synthesizing crotonin from cheap and easily available raw materials can avoid the tedious steps of separation and extraction from natural products, and can also solve the problems of low yield in existing chemical synthesis methods. It can expand the source of crotonin, thereby expanding its The scope of application is of great significance.
发明内容Contents of the invention
为了解决现有技术的不足,本发明提供了以2-硝基嘌呤衍生物为原料,在乙酰羟肟酸和碱金属或碱土金属的碳酸盐M2CO3存在下,有机溶剂中加热反应,得到巴豆苷及其类似物。而2-硝基嘌呤衍生物可通过廉价嘌呤核苷,通过四丁基硝酸铵/三氟甲磺酸酐体系合成,有较多报道,方法成熟便捷。通过采用该方法得到巴豆苷及其类似物,成本低,操作简便,反应条件温和,底物适应性好,表明了该合成方法的优越性和简便性。In order to solve the deficiencies of the prior art, the present invention provides a heating reaction in an organic solvent using 2-nitropurine derivatives as raw materials in the presence of acetohydroxamic acid and alkali metal or alkaline earth metal carbonate M 2 CO 3 , to obtain crotonin and its analogues. 2-nitropurine derivatives can be synthesized from cheap purine nucleosides through the tetrabutylammonium nitrate/trifluoromethanesulfonic anhydride system. There are many reports, and the method is mature and convenient. By using this method to obtain crotonin and its analogues, the cost is low, the operation is simple, the reaction conditions are mild, and the substrate adaptability is good, which demonstrates the superiority and simplicity of the synthesis method.
本发明的技术方案是:一种巴豆苷及其类似物的合成方法,通过以下反应方程式进行合成:The technical solution of the present invention is: a synthesis method of crotonin and its analogues, which is synthesized through the following reaction equation:
其中:M选自碱金属或碱土金属;R1选自氢、烷基、烯丙基、苄基、2-氯苄基、P选自氢、乙酰基或苯甲酰基;R2选自氢、氯、氟、甲氧基或氨基。Wherein: M is selected from alkali metal or alkaline earth metal; R 1 is selected from hydrogen, alkyl, allyl, benzyl, 2-chlorobenzyl, P is selected from hydrogen, acetyl or benzoyl; R 2 is selected from hydrogen, chlorine, fluorine, methoxy or amino.
包括以下步骤:以2-硝基嘌呤衍生物A为原料,在乙酰羟肟酸和M2CO3存在下,有机溶剂中加热反应,得到巴豆苷及其类似物B;The method includes the following steps: using 2-nitropurine derivative A as a raw material, heating and reacting in an organic solvent in the presence of acetohydroxamic acid and M 2 CO 3 to obtain crotonin and its analogue B;
进一步地,在上述技术方案中,M2CO3选自Na2CO3、K2CO3或Cs2CO3。Further, in the above technical solution, M 2 CO 3 is selected from Na 2 CO 3 , K 2 CO 3 or Cs 2 CO 3 .
进一步地,在上述技术方案中,2-硝基嘌呤衍生物A、乙酰羟肟酸与M2CO3摩尔比为1:1.5~4.5:2~6。Further, in the above technical solution, the molar ratio of 2-nitropurine derivative A, acetohydroxamic acid and M 2 CO 3 is 1:1.5~4.5:2~6.
进一步地,在上述技术方案中,所述有机溶剂选自水、乙醇、甲醇、乙腈、二甲基亚砜中的一种或多种。Further, in the above technical solution, the organic solvent is selected from one or more of water, ethanol, methanol, acetonitrile, and dimethyl sulfoxide.
进一步地,在上述技术方案中,反应温度为50-100℃,反应时间为2~24h。Further, in the above technical solution, the reaction temperature is 50-100°C, and the reaction time is 2-24 hours.
进一步地,在上述技术方案中,所述产物出于结构描述方便,本申请中均以结构B表示。Further, in the above technical solution, the product For the convenience of structural description, structure B is used in this application.
通过采用该方法得到巴豆苷及其类似物,成本低,操作简便,反应条件温和,底物适应性好,表明了该合成方法的优越性和简便性。By using this method to obtain crotonin and its analogues, the cost is low, the operation is simple, the reaction conditions are mild, and the substrate adaptability is good, which demonstrates the superiority and simplicity of the synthesis method.
根据化学反应的基本原理,2-硝基转化为2-羟基的方法为水解反应,而为了增加羟基的亲核性,需要高浓度的氢氧化钠、四丁基氢氧化铵等强碱。乙酰羟肟酸可以和弱碱碳酸钾等反应,氧原子具有较好的亲核性,可以和2-硝基反应,得到中间体III,而III不稳定,随机重排得到目标产物II。采用方程式表示如下:According to the basic principles of chemical reactions, the method for converting 2-nitro group into 2-hydroxyl group is hydrolysis reaction. In order to increase the nucleophilicity of hydroxyl group, strong bases such as high concentration sodium hydroxide and tetrabutylammonium hydroxide are required. Acetohydroxamic acid can react with weak bases such as potassium carbonate. The oxygen atom has good nucleophilicity and can react with the 2-nitro group to obtain intermediate III. However, III is unstable and randomly rearranges to obtain the target product II. The equation is expressed as follows:
在反应过程中,乙酰氨基增加了氧原子的亲核性,弥补了高浓度的氢氧化钠、四丁基氢氧化铵等强碱的不足。During the reaction process, acetylamino increases the nucleophilicity of oxygen atoms, making up for the shortcomings of strong bases such as high-concentration sodium hydroxide and tetrabutylammonium hydroxide.
具体实施方式Detailed ways
下面结合实施例对本发明做详细说明。The present invention will be described in detail below with reference to examples.
实施例1:Example 1:
在反应瓶内,加入(0.312g,1mmol)、乙酰羟肟酸(0.15g,2mmol)和碳酸钾(0.345g,2.5mmol),加入到乙腈(10mL)中,油浴锅中加热到80℃反应4h,TLC显示原料反应完全,将反应液减压浓缩,水重结晶得到/>0.251g,收率89%。白色固体,m.p.238-240℃.1HNMR(DMSO-d6,400MHz)δ10.88(s,1H),8.37(s,1H),7.83(brs,2H),5.81(d,J=6.0Hz,1H),5.47(d,J=6.0Hz,1H),5.19(d,J=4.8Hz,1H),5.05(t,J=4.8Hz,1H),4.52-4.48(m,1H),4.12-4.09(m,1H),3.93(d,J=3.6Hz,1H),3.67-3.52(m,2H);13CNMR(DMSO-d6,100MHz)δ160.2,156.0,151.6,137.1,112.4,84.1,83.3,75.6,61.1.In the reaction bottle, add (0.312g, 1mmol), acetohydroxamic acid (0.15g, 2mmol) and potassium carbonate (0.345g, 2.5mmol) were added to acetonitrile (10mL), heated to 80°C in an oil bath and reacted for 4h. TLC showed that the raw materials When the reaction is complete, the reaction solution is concentrated under reduced pressure and recrystallized from water to obtain /> 0.251g, yield 89%. White solid, mp238-240℃. 1 HNMR (DMSO-d 6 ,400MHz) δ10.88(s,1H),8.37(s,1H),7.83(brs,2H),5.81(d,J=6.0Hz, 1H),5.47(d,J=6.0Hz,1H),5.19(d,J=4.8Hz,1H),5.05(t,J=4.8Hz,1H),4.52-4.48(m,1H),4.12- 4.09(m,1H),3.93(d,J=3.6Hz,1H),3.67-3.52(m,2H); 13 CNMR(DMSO-d 6 ,100MHz)δ160.2,156.0,151.6,137.1,112.4,84.1, 83.3,75.6,61.1.
实施例2:以1mmol为原料,改变其他反应条件,反应结果如下表:Example 2: With 1 mmol As raw materials, changing other reaction conditions, the reaction results are as follows:
实施例3:Example 3:
在反应瓶内,加入(0.255g,1mmol)、乙酰羟肟酸(0.187g,2.5mmol)和碳酸钠(0.318g,3mmol),加入到乙腈(10mL)中,油浴锅中加热到80℃反应6h,TLC显示原料反应完全,将反应液减压浓缩,乙醇重结晶得到/>0.21g,收率93%。白色固体,m.p.168-170℃.1HNMR(DMSO-d6,400MHz)δ10.42(s,1H),9.25(s,1H),8.21(s,H),7.37-7.31(m,5H),3.81(s,2H),;13CNMR(100MHz,DMSO-d6)δ152.2,151.4,150.8,142.6,134.2,131.1,129.1,128.9,127.4,47.8.In the reaction bottle, add (0.255g, 1mmol), acetohydroxamic acid (0.187g, 2.5mmol) and sodium carbonate (0.318g, 3mmol) were added to acetonitrile (10mL), heated to 80°C in an oil bath and reacted for 6 hours. TLC showed that the raw materials When the reaction is complete, the reaction solution is concentrated under reduced pressure and recrystallized from ethanol to obtain /> 0.21g, yield 93%. White solid, mp168-170℃. 1 HNMR (DMSO-d 6 ,400MHz) δ10.42(s,1H),9.25(s,1H),8.21(s,H),7.37-7.31(m,5H), 3.81(s,2H),; 13 CNMR(100MHz,DMSO-d 6 )δ152.2,151.4,150.8,142.6,134.2,131.1,129.1,128.9,127.4,47.8.
实施例4:Example 4:
在反应瓶内,加入(0.312g,1mmol)、乙酰羟肟酸(0.337g,4.5mmol)和碳酸钾(0.828g,6mmol),加入到H2O(20mL)中,油浴锅中加热到80℃反应6h,TLC显示原料反应完全,将反应液减压浓缩,水重结晶得到/>0.212g,收率75%。In the reaction bottle, add (0.312g, 1mmol), acetohydroxamic acid (0.337g, 4.5mmol) and potassium carbonate (0.828g, 6mmol) were added to H 2 O (20mL), heated to 80°C in an oil bath and reacted for 6h, TLC It shows that the reaction of the raw materials is complete, the reaction solution is concentrated under reduced pressure, and the water is recrystallized to obtain /> 0.212g, yield 75%.
实施例5:Example 5:
在反应瓶内,加入(0.209g,1mmol)、乙酰羟肟酸(0.187g,2.5mmol)和碳酸钠(0.318g,3mmol),加入到乙醇(10mL)中,油浴锅中加热到80℃反应6h,TLC显示原料反应完全,将反应液减压浓缩,柱层析得到/>0.162g,收率90%。白色固体,m.p.182-184℃.1HNMR(DMSO-d6,400MHz)δ10.49(s,1H),8.18(s,H),4.16(s,3H),3.76(s,3H);13CNMR(100MHz,DMSO-d6)δ158.6,152.4,149.8,142.0,114.2,54.3,31.7.In the reaction bottle, add (0.209g, 1mmol), acetohydroxamic acid (0.187g, 2.5mmol) and sodium carbonate (0.318g, 3mmol) were added to ethanol (10mL), heated to 80°C in an oil bath and reacted for 6h. TLC showed that the raw materials When the reaction is complete, the reaction solution is concentrated under reduced pressure and subjected to column chromatography to obtain/> 0.162g, yield 90%. White solid, mp182-184℃. 1 HNMR (DMSO-d 6 ,400MHz) δ10.49(s,1H),8.18(s,H),4.16(s,3H),3.76(s,3H); 13 CNMR (100MHz, DMSO-d 6 )δ158.6,152.4,149.8,142.0,114.2,54.3,31.7.
以上显示和描述了本发明的基本原理和主要特征和本发明的优点。本行业的技术人员应该了解,本发明不受上述实施例的限制,上述实施例和说明书中描述的只是说明本发明的原理,在不脱离本发明精神和范围的前提下,本发明还会有各种变化和改进,这些变化和改进都落入要求保护的本发明范围内。本发明要求保护范围由所附的权利要求书及其等效物界定。The basic principles and main features of the present invention and the advantages of the present invention have been shown and described above. Those skilled in the industry should understand that the present invention is not limited by the above embodiments. The above embodiments and descriptions only illustrate the principles of the present invention. Without departing from the spirit and scope of the present invention, the present invention will also have other aspects. Various changes and modifications are possible, which fall within the scope of the claimed invention. The scope of protection of the present invention is defined by the appended claims and their equivalents.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310935349.3A CN116947948A (en) | 2023-07-28 | 2023-07-28 | Synthesis method of crotonoside and analogues thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310935349.3A CN116947948A (en) | 2023-07-28 | 2023-07-28 | Synthesis method of crotonoside and analogues thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116947948A true CN116947948A (en) | 2023-10-27 |
Family
ID=88454417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310935349.3A Pending CN116947948A (en) | 2023-07-28 | 2023-07-28 | Synthesis method of crotonoside and analogues thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116947948A (en) |
-
2023
- 2023-07-28 CN CN202310935349.3A patent/CN116947948A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001011092A (en) | Synthesis of nucleoside analog | |
WO2008144980A1 (en) | The preparation method and intermediates of capecitabine | |
US8193354B2 (en) | Process for preparation of Gemcitabine hydrochloride | |
CN108424433B (en) | Alpha nucleoside synthesis method | |
WO2023138079A1 (en) | Preparation method for 2'-substituted pyrimidine nucleoside | |
CN116947948A (en) | Synthesis method of crotonoside and analogues thereof | |
JP7475056B2 (en) | Method for producing photoresponsive nucleotide analogues | |
Hu et al. | A convenient and cost efficient route suitable for “one-pot” synthesis of molnupiravir | |
US20150065700A1 (en) | Method for preparing 3-o-benzyl-1,2-o-isopropylidene-a-l-furan idose | |
EP1634882A1 (en) | Inosine derivative and process for producing the same | |
CN104744537A (en) | Synthetic method of capecitabine | |
CN110655506A (en) | Preparation method of tegafur | |
JP6947354B2 (en) | How to make linagliptin | |
CN111848423B (en) | Preparation method of tert-butyl 3-oxocyclobutylcarbamate | |
JP2007510696A (en) | Method for producing 1-chloro-3,5-di-O-acyl-2-deoxy-L-ribofuranoside derivative | |
CN113637003A (en) | Method for preparing 2-amino-6- (piperidine-4-acyl) pyridine derivative | |
JP2666160B2 (en) | 5-O-pyrimidyl-2,3-dideoxy-1-thiofuranoside derivative, method for producing the same and use | |
KR101241321B1 (en) | Improved preparation method of Decitabine | |
CN103319556A (en) | Method for chemically preparing 2'-desoxyadenossine | |
JPH03227997A (en) | Production of nucleoside derivative | |
RU2324699C1 (en) | PROCESS OF OBTAINING 2,6- DICHLOR-9-(2,3,5-TRI-O-ACETYL-β-D-RIBOFURANOZYL) PURINE | |
JP2005538080A (en) | Method for synthesizing 2-deoxy-L-ribose | |
KR100481356B1 (en) | Method of preparing 2'-o-substituted nucleoside | |
CN114605262A (en) | A kind of efficient and selective synthesis method of phenylallyl ether compounds | |
WO2020263660A1 (en) | Process for the preparation of 2-fluoroadenine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |